People with the rare Li-Fraumeni syndrome (LFS) have a high risk of developing cancer. Almost all those affected will develop ...

With help from Alberta Health Services, the NWT Health and Social Services Authority (NTHSSA) has secured funding to support bringing hematology oncology physician and nursing positions back in the ...

Takeda’s revamped R&D strategy means the drugmaker’s oncology leaders are prioritizing work in tumors across thoracic, gastrointestinal (GI) and hematology, while pushing the Japanese company’s cell ...

A patient on Long Island is the first in New York to be cured of sickle cell anemia, doctors say. They credit state-of-the-art genetic treatment. For 21 years, Sebastien Beauzile suffered chronic pain ...

March is Colorectal Cancer Awareness Month, and New York Oncology Hematology is raising awareness about the importance of getting screened early.The organization is holding a fundraising event on ...

The 340B federal drug pricing program has transformed into a system benefiting large hospital systems and corporate middlemen ...

A young man from Laurelton is the first New Yorker with sickle cell disease to receive Lyfgenia, a life-changing gene therapy treatment that has wiped away the debilitating illness, The Post first ...

Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, ...

Bionano Genomics (BNGO) announced a study published in the American Journal of Hematology demonstrating the potential utility of optical genome ...

Nature's Toolbox (NTx), a life sciences company developing next-generation platforms for RNA and protein manufacturing, today announced the founding of its Scientific Advisory Board (SAB) with ...

Momentum Builds Across Programs with Key Data Milestones Expected in 2025Cemacabtagene Ansegedleucel (Cema-Cel): First-Line ...

Dr. Alan Tan explores circulating tumor DNA, its role in clinical trials and its potential impact on patients with renal cell ...